Skip to main navigation Skip to search Skip to main content

Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021

  • Overcoming COVID-19 Investigators

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)52-58
Number of pages7
JournalMorbidity and Mortality Weekly Report
Volume71
Issue number2
DOIs
StatePublished - Jan 14 2022

Cite this